



Director/PDMR Dealing

May 21, 2021

RNS Number : 4140Z

Renalytix AI PLC

21 May 2021

Renalytix AI plc

("Renalytix" or the "Company")

Director/PDMR Dealing

New York, 21 May 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by James McCullough, the Company's Chief Executive Officer, of 54,538 American Depositary Shares ("**ADS**"), each representing two ordinary shares of £0.0025 each in the capital of the Company ("**Ordinary Shares**"), under a Rule 10b5-1 trading plan established in accordance with Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("**MAR**").

Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, or inside information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future.

Following completion of the sale, James McCullough is interested in 2,761,034 Ordinary Shares representing 3.83% of the current issued share capital of the Company. This includes shares held by his family trust, The McCullough 2020 Irrevocable Trust.

The information contained in this notification is disclosed in accordance with the requirements of MAR.

| | | |
|----|---|-------------------------|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | James McCullough |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |

| | | | |
|----|---|--|--|
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) | Name | Renalytix AI plc | |
| b) | Legal Entity Identifier | 213800NTOH3FK3WER551 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a) | Description of the financial instrument, type of instrument Identification code | ADS', each ADS representing two Ordinary Shares of £0.0025 each. US75973T1016 | |
| b) | Nature of the transaction | Sale of ADS' under a 10b5-1 trading plan | |
| c) | Currency | US Dollar | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | \$30.46726 | 15,000 ADS (representing 30,000 Ordinary Shares) |
| | | \$30.512611 | 25,000 ADS (representing 50,000 Ordinary Shares) |
| e) | Aggregated information - Aggregated volume - Price - Aggregated total | 40,000 ADS (representing 80,000 Ordinary Shares) \$30.495605 \$1,219,824.20 | |
| f) | Date of the transaction | 19 May 2021 | |
| g) | Place of the transaction | Nasdaq Stock Exchange | |

| | | |
|----------|--|-------------------------|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | James McCullough |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |

| | | | |
|----|---|--|---|
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) | Name | Renalytix AI plc | |
| b) | Legal Entity Identifier | 213800NTOH3FK3WER551 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a) | Description of the financial instrument, type of instrument Identification code | ADS', each ADS representing two Ordinary Shares of £0.0025 each. US75973T1016 | |
| b) | Nature of the transaction | Sale of ADS under a 10b5-1 trading plan | |
| c) | Currency | US Dollar | |
| d) | Price(s) and volume(s) | Price(s) \$32.322238 | Volume(s) 14,538 ADS (representing 29,076 Ordinary Shares) |
| e) | Aggregated information - Aggregated volume - Price - Aggregated total | 14,538 ADS (representing 29,076 Ordinary Shares \$32.322238 \$469,900.70 | |
| f) | Date of the transaction | 20 May 2021 | |
| g) | Place of the transaction | Nasdaq Stock Exchange | |

For further information, please contact:

Renalytix

James McCullough, CEO

www.renalytixai.com

Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)

Gary Clarence / Daniel Adams

Tel: 020 7597 4000

Walbrook PR Limited

Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07584 391 303

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

* <https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html>

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHKZGZKKMLGMZG